Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
<levobupivacaine, mechanism, phenytoin>, <levobupivacaine, mechanism, phenobarbital>, <levobupivacaine, mechanism, rifampin>, <levobupivacaine, mechanism, ketoconazole>